【关键词】慢性心力衰竭；心功能；沙库巴曲缬沙坦；β- 内啡肽；心肌营养素 -1
Efficacy and Safety of Sacubitril / Valsartan for Chronic Heart Failure JIANG Yang, DONG Peng* , LIU Fang, YAN Ping Department of Cardiology, Aviation General Hospital, Beijing 100012, China 【Abstract】Objective To investigate the efficacy, safety and influencing factors of Sacubitril / Valsartan in the treatment of chronic heart failure, and to observe its effect on 1-year survival rate. Methods 96 patients with chronic heart failure who were continuously hospitalized in our hospital from May 2017 to April 2019 were divided into two groups. The control group was treated with conventional anti-heart failure treatment. The treatment group was treated with conventional anti-heart failure + Sacubitril / Valsartan. After 3 months of treatment, the efficacy and safety were evaluated. The primary endpoint was the difference of efficacy between the two groups. The secondary endpoints were: ① Changes in echocardiography-related praameters before and after treatment: left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter ( LVEDD), left atrial inner diameter (LA), ratio of maximum peak blood flow (E / A) during early and late diastole, and maximum peak value during early diastole (E / e´); ② serum biomarkers before and after treatment including β-endorphin (β-EP), cardiac trophin-1(CT-1), and N-terminal pronatriuretic peptide (NT-proBNP); ③ the difference of survival rate between the two groups after one year treatment. Results Compared with the control group, the efficacy of the treatment group was significantly improved after 3 months treatment (95.8 % vs 83.3 %, P< 0.05). LVEF and E/A level in the treatment group was significantly improved (P< 0.05), LVEDD, LA and E/ E ´ levels was significantly decreased (P< 0.05) comparison with the control group. Also serum level of β-EP, CT-1 and NT-proBNP significantly decreased when compared with the control group (P < 0.05). After 1 year follow-up, patients in the treatment group had a significantly better survival probability than those in control group (83.7% vs 65.9%, P < 0.05). Conclusion Sacubitril / Valsartan can significantly improve the short-term efficacy and one-year survival rate of patients with chronic heart failure. 【Key Words】Chronic heart failure; Cardiac function; Sacubitril / Valsartan; β-endorphin; Cardiac trophin-1
 |
沙库巴曲缬沙坦治疗慢性心力衰竭的有效性及安全性研究_姜阳 .pdf |
